Janika Viereck
Head of R&D, Cardior Pharmaceuticals GmbH

As the number of approved oligonucleotides has increased, CDMOs have responded by expanding manufacturing capacity. Do you feel the market has adequate manufacturing capacity to meet the current and near term demands of oligonucleotide drug developers?
CDMOs are currently putting extensive efforts in expanding their capacities to meet the demand in oligo projects. And with the extending capacities and new competition rising in the oligo CDMO field, also the pricing models become continuously more attractive to the pharma customers. For early-stage development products this seems to fit very well to the current progression in clinical phases, as these projects are usually not needing a metric ton manufacturing scale. However, when projecting current oligo projects in development to a stage when they reach marketing, we see that traditional manufacturing methods like solid phase ... ...